{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:24:09Z","timestamp":1778073849806,"version":"3.51.4"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bundeswehr","award":["IMB-59-2016-STAN"],"award-info":[{"award-number":["IMB-59-2016-STAN"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virus Genes"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11262-020-01820-x","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T22:27:23Z","timestamp":1613687243000},"page":"133-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prophylactic strategies to control chikungunya virus infection"],"prefix":"10.1007","volume":"57","author":[{"given":"Friederike I. L.","family":"Hucke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malena","family":"Bestehorn-Willmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-3211","authenticated-orcid":false,"given":"Joachim J.","family":"Bugert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"Pt 2","key":"1820_CR1","first-page":"471","volume":"81","author":"AM Powers","year":"2000","unstructured":"Powers AM et al (2000) Re-emergence of chikungunya and O\u2019nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J Gen Virol 81(Pt 2):471\u2013479","journal-title":"J Gen Virol"},{"issue":"2","key":"1820_CR2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/v10020089","volume":"10","author":"RS Brown","year":"2018","unstructured":"Brown RS, Wan JJ, Kielian M (2018) The alphavirus exit pathway: what we know and what we wish we knew. Viruses 10(2):89","journal-title":"Viruses"},{"issue":"2","key":"1820_CR3","first-page":"471","volume":"81","author":"AM Powers","year":"2000","unstructured":"Powers AM et al (2000) Re-emergence of chikungunya and o\u2019nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J Gen Virol 81(2):471\u2013479","journal-title":"J Gen Virol"},{"issue":"5","key":"1820_CR4","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/molbev\/msaa015","volume":"37","author":"BQ Minh","year":"2020","unstructured":"Minh BQ et al (2020) IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol 37(5):1530\u20131534","journal-title":"Mol Biol Evol"},{"issue":"6","key":"1820_CR5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nmeth.4285","volume":"14","author":"S Kalyaanamoorthy","year":"2017","unstructured":"Kalyaanamoorthy S et al (2017) ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods 14(6):587\u2013589","journal-title":"Nat Methods"},{"issue":"3","key":"1820_CR6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","volume":"58","author":"JH Strauss","year":"1994","unstructured":"Strauss JH, Strauss EG (1994) The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58(3):491\u2013562","journal-title":"Microbiol Rev"},{"issue":"Pt 12","key":"1820_CR7","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1099\/0022-1317-83-12-3075","volume":"83","author":"AH Khan","year":"2002","unstructured":"Khan AH et al (2002) Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. J Gen Virol 83(Pt 12):3075\u20133084","journal-title":"J Gen Virol"},{"issue":"3","key":"1820_CR8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","volume":"127","author":"LA Silva","year":"2017","unstructured":"Silva LA, Dermody TS (2017) Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest 127(3):737\u2013749","journal-title":"J Clin Invest"},{"key":"1820_CR9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virusres.2017.01.007","volume":"234","author":"MK Pietila","year":"2017","unstructured":"Pietila MK, Hellstrom K, Ahola T (2017) Alphavirus polymerase and RNA replication. Virus Res 234:44\u201357","journal-title":"Virus Res"},{"issue":"1","key":"1820_CR10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0035-9203(55)90080-8","volume":"49","author":"MC Robinson","year":"1955","unstructured":"Robinson MC (1955) An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952\u201353. I. Clinical features. Trans R Soc Trop Med Hyg 49(1):28\u201332","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"11","key":"1820_CR11","doi-asserted-by":"crossref","first-page":"e0004101","DOI":"10.1371\/journal.pntd.0004101","volume":"9","author":"G Kuno","year":"2015","unstructured":"Kuno G (2015) A re-examination of the history of etiologic confusion between dengue and chikungunya. PLoS Negl Trop Dis 9(11):e0004101","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"1820_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/v11020175","volume":"11","author":"G Matusali","year":"2019","unstructured":"Matusali G et al (2019) Tropism of the chikungunya virus. Viruses 11(2):175","journal-title":"Viruses"},{"issue":"7","key":"1820_CR13","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1371\/journal.pmed.0030263","volume":"3","author":"I Schuffenecker","year":"2006","unstructured":"Schuffenecker I et al (2006) Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 3(7):e263","journal-title":"PLoS Med"},{"issue":"1","key":"1820_CR14","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/s41467-018-03332-7","volume":"9","author":"BM Althouse","year":"2018","unstructured":"Althouse BM et al (2018) Role of monkeys in the sylvatic cycle of chikungunya virus in Senegal. Nat Commun 9(1):1046","journal-title":"Nat Commun"},{"issue":"4","key":"1820_CR15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.coviro.2011.07.004","volume":"1","author":"KA Tsetsarkin","year":"2011","unstructured":"Tsetsarkin KA et al (2011) Chikungunya virus: evolution and genetic determinants of emergence. Curr Opin Virol 1(4):310\u2013317","journal-title":"Curr Opin Virol"},{"issue":"9","key":"1820_CR16","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3201\/eid2109.150439","volume":"21","author":"IC Sam","year":"2015","unstructured":"Sam IC et al (2015) Chikungunya virus in macaques, Malaysia. Emerg Infect Dis 21(9):1683\u20131685","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"1820_CR17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.4269\/ajtmh.2010.09-0577","volume":"83","author":"M Mavale","year":"2010","unstructured":"Mavale M et al (2010) Venereal transmission of chikungunya virus by Aedes aegypti mosquitoes (Diptera: Culicidae). Am J Trop Med Hyg 83(6):1242\u20131244","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"1820_CR18","doi-asserted-by":"crossref","first-page":"e0004139","DOI":"10.1371\/journal.pntd.0004139","volume":"9","author":"D Acharya","year":"2015","unstructured":"Acharya D et al (2015) Loss of glycosaminoglycan receptor binding after mosquito cell passage reduces chikungunya virus infectivity. PLoS Negl Trop Dis 9(10):e0004139","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"1820_CR19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.medmal.2011.12.002","volume":"42","author":"P Renault","year":"2012","unstructured":"Renault P et al (2012) Epidemiology of chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Med Mal Infect 42(3):93\u2013101","journal-title":"Med Mal Infect"},{"issue":"11","key":"1820_CR20","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3201\/eid2211.160404","volume":"22","author":"CF Yang","year":"2016","unstructured":"Yang CF et al (2016) Imported chikungunya virus strains, Taiwan, 2006\u20132014. Emerg Infect Dis 22(11):1981\u20131984","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"1820_CR21","first-page":"E070906.1","volume":"12","author":"R Angelini","year":"2007","unstructured":"Angelini R et al (2007) An outbreak of chikungunya fever in the province of Ravenna, Italy. Euro Surveill 12(9):E070906.1","journal-title":"Euro Surveill"},{"issue":"5","key":"1820_CR22","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3201\/eid1705.101873","volume":"17","author":"M Grandadam","year":"2011","unstructured":"Grandadam M et al (2011) Chikungunya virus, southeastern France. Emerg Infect Dis 17(5):910\u2013913","journal-title":"Emerg Infect Dis"},{"issue":"28","key":"1820_CR23","first-page":"20854","volume":"19","author":"S Cauchemez","year":"2014","unstructured":"Cauchemez S et al (2014) Local and regional spread of chikungunya fever in the Americas. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 19(28):20854\u201320854","journal-title":"Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin"},{"key":"1820_CR24","unstructured":"ECDC (2020) Chikungunya worldwide overview: geographical distribution of chikungunya cases reported worldwide, July 2020 Situation update, 17 July 2020. Available from: https:\/\/www.ecdc.europa.eu\/en\/chikungunya-monthly"},{"issue":"3","key":"1820_CR25","doi-asserted-by":"crossref","first-page":"e4691","DOI":"10.1371\/journal.pone.0004691","volume":"4","author":"F Pages","year":"2009","unstructured":"Pages F et al (2009) Aedes albopictus mosquito: the main vector of the 2007 chikungunya outbreak in Gabon. PLoS ONE 4(3):e4691","journal-title":"PLoS ONE"},{"issue":"6","key":"1820_CR26","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/jme\/tjx156","volume":"54","author":"M Mogi","year":"2017","unstructured":"Mogi M et al (2017) The climate range expansion of Aedes albopictus (Diptera: Culicidae) in Asia inferred from the distribution of Albopictus subgroup species of Aedes (Stegomyia). J Med Entomol 54(6):1615\u20131625","journal-title":"J Med Entomol"},{"issue":"12","key":"1820_CR27","doi-asserted-by":"crossref","first-page":"e0004305","DOI":"10.1371\/journal.pntd.0004305","volume":"9","author":"N Sahadeo","year":"2015","unstructured":"Sahadeo N et al (2015) Correction: molecular characterisation of chikungunya virus infections in trinidad and comparison of clinical and laboratory features with dengue and other acute febrile cases. PLoS Negl Trop Dis 9(12):e0004305","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"1820_CR28","doi-asserted-by":"crossref","first-page":"02449-17","DOI":"10.1128\/mBio.02449-17","volume":"9","author":"RM Langsjoen","year":"2018","unstructured":"Langsjoen RM et al (2018) Chikungunya virus strains show lineage-specific variations in virulence and cross-protective ability in murine and nonhuman primate models. mBio 9(2):02449\u201317","journal-title":"mBio"},{"issue":"12","key":"1820_CR29","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1371\/journal.ppat.0030201","volume":"3","author":"KA Tsetsarkin","year":"2007","unstructured":"Tsetsarkin KA et al (2007) A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 3(12):e201","journal-title":"PLoS Pathog"},{"issue":"8","key":"1820_CR30","doi-asserted-by":"crossref","first-page":"e6835","DOI":"10.1371\/journal.pone.0006835","volume":"4","author":"KA Tsetsarkin","year":"2009","unstructured":"Tsetsarkin KA et al (2009) Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedesalbopictus and Ae. aegypti mosquitoes. PLoS ONE 4(8):e6835\u2013e6835","journal-title":"PLoS ONE"},{"key":"1820_CR31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1743-422X-7-189","volume":"7","author":"KP Niyas","year":"2010","unstructured":"Niyas KP et al (2010) Molecular characterization of chikungunya virus isolates from clinical samples and adult Aedesalbopictus mosquitoes emerged from larvae from Kerala, South India. Virol J 7:189\u2013189","journal-title":"Virol J"},{"issue":"6","key":"1820_CR32","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1128\/JVI.02060-07","volume":"82","author":"DJ Pierro","year":"2008","unstructured":"Pierro DJ, Powers EL, Olson KE (2008) Genetic determinants of Sindbis virus mosquito infection are associated with a highly conserved alphavirus and flavivirus envelope sequence. J Virol 82(6):2966\u20132974","journal-title":"J Virol"},{"issue":"12","key":"1820_CR33","doi-asserted-by":"crossref","first-page":"e1002412","DOI":"10.1371\/journal.ppat.1002412","volume":"7","author":"KA Tsetsarkin","year":"2011","unstructured":"Tsetsarkin KA, Weaver SC (2011) Sequential adaptive mutations enhance efficient vector switching by chikungunya virus and its epidemic emergence. PLoS Pathog 7(12):e1002412\u2013e1002412","journal-title":"PLoS Pathog"},{"issue":"31","key":"1820_CR34","doi-asserted-by":"crossref","first-page":"11344","DOI":"10.1073\/pnas.0402905101","volume":"101","author":"AC Brault","year":"2004","unstructured":"Brault AC et al (2004) Venezuelan equine encephalitis emergence: enhanced vector infection from a single amino acid substitution in the envelope glycoprotein. Proc Natl Acad Sci USA 101(31):11344\u201311349","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1820_CR35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1083\/jcb.140.1.91","volume":"140","author":"M Vashishtha","year":"1998","unstructured":"Vashishtha M et al (1998) A single point mutation controls the cholesterol dependence of Semliki Forest virus entry and exit. J Cell Biol 140(1):91\u201399","journal-title":"J Cell Biol"},{"issue":"6","key":"1820_CR36","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1371\/journal.ppat.0030089","volume":"3","author":"M Sourisseau","year":"2007","unstructured":"Sourisseau M et al (2007) Characterization of reemerging chikungunya virus. PLoS Pathog 3(6):e89","journal-title":"PLoS Pathog"},{"key":"1820_CR37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.meegid.2017.08.032","volume":"55","author":"S Wichit","year":"2017","unstructured":"Wichit S et al (2017) AedesAegypti saliva enhances chikungunya virus replication in human skin fibroblasts via inhibition of the type I interferon signaling pathway. Infect Genet Evol 55:68\u201370","journal-title":"Infect Genet Evol"},{"issue":"7706","key":"1820_CR38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41586-018-0121-3","volume":"557","author":"R Zhang","year":"2018","unstructured":"Zhang R et al (2018) Mxra8 is a receptor for multiple arthritogenic alphaviruses. Nature 557(7706):570\u2013574","journal-title":"Nature"},{"issue":"3","key":"1820_CR39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1172\/JCI40104","volume":"120","author":"K Labadie","year":"2010","unstructured":"Labadie K et al (2010) Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 120(3):894\u2013906","journal-title":"J Clin Invest"},{"key":"1820_CR40","doi-asserted-by":"crossref","first-page":"32288","DOI":"10.1038\/srep32288","volume":"6","author":"M Ruiz Silva","year":"2016","unstructured":"Ruiz Silva M et al (2016) Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells. Sci Rep 6:32288","journal-title":"Sci Rep"},{"issue":"6","key":"1820_CR41","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1371\/journal.pone.0000527","volume":"2","author":"S Ozden","year":"2007","unstructured":"Ozden S et al (2007) Human muscle satellite cells as targets of chikungunya virus infection. PLoS ONE 2(6):e527","journal-title":"PLoS ONE"},{"issue":"2","key":"1820_CR42","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.ppat.0040029","volume":"4","author":"T Couderc","year":"2008","unstructured":"Couderc T et al (2008) A mouse model for chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4(2):e29","journal-title":"PLoS Pathog"},{"key":"1820_CR43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1743-422X-5-31","volume":"5","author":"S Lokireddy","year":"2008","unstructured":"Lokireddy S, Vemula S, Vadde R (2008) Connective tissue metabolism in chikungunya patients. Virol J 5:31","journal-title":"Virol J"},{"issue":"15","key":"1820_CR44","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.1128\/JVI.01032-14","volume":"88","author":"P Pal","year":"2014","unstructured":"Pal P et al (2014) Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol 88(15):8213\u20138226","journal-title":"J Virol"},{"issue":"3","key":"1820_CR45","doi-asserted-by":"crossref","first-page":"e1978","DOI":"10.1002\/rmv.1978","volume":"28","author":"R Mehta","year":"2018","unstructured":"Mehta R et al (2018) The neurological complications of chikungunya virus: a systematic review. Rev Med Virol 28(3):e1978","journal-title":"Rev Med Virol"},{"issue":"3","key":"1820_CR46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12028-017-0413-8","volume":"27","author":"T Cerny","year":"2017","unstructured":"Cerny T et al (2017) The range of neurological complications in chikungunya fever. Neurocrit Care 27(3):447\u2013457","journal-title":"Neurocrit Care"},{"issue":"Pt 2","key":"1820_CR47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1099\/vir.0.071175-0","volume":"96","author":"T Das","year":"2015","unstructured":"Das T et al (2015) Multifaceted innate immune responses engaged by astrocytes, microglia and resident dendritic cells against chikungunya neuroinfection. J Gen Virol 96(Pt 2):294\u2013310","journal-title":"J Gen Virol"},{"issue":"2","key":"1820_CR48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s13365-015-0378-3","volume":"22","author":"FM Inglis","year":"2016","unstructured":"Inglis FM et al (2016) Neuropathogenesis of chikungunya infection: astrogliosis and innate immune activation. J Neurovirol 22(2):140\u2013148","journal-title":"J Neurovirol"},{"issue":"1","key":"1820_CR49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.15252\/emmm.201404459","volume":"7","author":"Z Her","year":"2015","unstructured":"Her Z et al (2015) Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. EMBO Mol Med 7(1):24\u201341","journal-title":"EMBO Mol Med"},{"issue":"12","key":"1820_CR50","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/acr.22900","volume":"68","author":"AJ Rodriguez-Morales","year":"2016","unstructured":"Rodriguez-Morales AJ et al (2016) Prevalence of post-chikungunya infection chronic inflammatory arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 68(12):1849\u20131858","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"1820_CR51","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.trstmh.2010.01.011","volume":"104","author":"SP Manimunda","year":"2010","unstructured":"Manimunda SP et al (2010) Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans R Soc Trop Med Hyg 104(6):392\u2013399","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"1820_CR52","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1017\/S0950268808001167","volume":"137","author":"A Economopoulou","year":"2009","unstructured":"Economopoulou A et al (2009) Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005\u20132006 outbreak on Reunion. Epidemiol Infect 137(4):534\u2013541","journal-title":"Epidemiol Infect"},{"issue":"1","key":"1820_CR53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1056\/NEJMc1505501","volume":"373","author":"F Simon","year":"2015","unstructured":"Simon F, Javelle E, Gasque P (2015) Chikungunya virus infections. N Engl J Med 373(1):93\u201394","journal-title":"N Engl J Med"},{"issue":"8","key":"1820_CR54","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3201\/eid1408.080201","volume":"14","author":"P Renault","year":"2008","unstructured":"Renault P, Josseran L, Pierre V (2008) Chikungunya-related fatality rates, Mauritius, India, and Reunion Island. Emerg Infect Dis 14(8):1327","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"1820_CR55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.0000000000002234","volume":"86","author":"P Gerardin","year":"2016","unstructured":"Gerardin P et al (2016) Chikungunya virus-associated encephalitis: a cohort study on La Reunion Island, 2005\u20132009. Neurology 86(1):94\u2013102","journal-title":"Neurology"},{"key":"1820_CR56","volume-title":"Preparedness and response for chikungunya virus introduction in the Americas","author":"R Barrera","year":"2011","unstructured":"Barrera R et al (2011) Preparedness and response for chikungunya virus introduction in the Americas. PAHO\/WHO, Washington, DC"},{"issue":"13","key":"1820_CR57","doi-asserted-by":"crossref","first-page":"20753","DOI":"10.2807\/1560-7917.ES2014.19.13.20753","volume":"19","author":"R Omarjee","year":"2014","unstructured":"Omarjee R et al (2014) Importance of case definition to monitor ongoing outbreak of chikungunya virus on a background of actively circulating dengue virus, St Martin, December 2013 to January 2014. Euro Surveill 19(13):20753","journal-title":"Euro Surveill"},{"issue":"4","key":"1820_CR58","first-page":"443","volume":"10","author":"M Kaur","year":"2018","unstructured":"Kaur M et al (2018) Coinfection of chikungunya and dengue viruses: a serological study from North Western region of Punjab, India. J Lab Phys 10(4):443\u2013447","journal-title":"J Lab Phys"},{"key":"1820_CR59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcv.2016.01.008","volume":"76","author":"S Jacobsen","year":"2016","unstructured":"Jacobsen S et al (2016) External quality assessment studies for laboratory performance of molecular and serological diagnosis of chikungunya virus infection. J Clin Virol 76:55\u201365","journal-title":"J Clin Virol"},{"issue":"suppl 5","key":"1820_CR60","doi-asserted-by":"crossref","first-page":"S471","DOI":"10.1093\/infdis\/jiw274","volume":"214","author":"BW Johnson","year":"2016","unstructured":"Johnson BW, Russell BJ, Goodman CH (2016) Laboratory diagnosis of chikungunya virus infections and commercial sources for diagnostic assays. J Infect Dis 214(suppl 5):S471\u2013S474","journal-title":"J Infect Dis"},{"key":"1820_CR61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijid.2019.11.001","volume":"91","author":"M Kikuti","year":"2020","unstructured":"Kikuti M et al (2020) Evaluation of two commercially available chikungunya virus IgM enzyme-linked immunoassays (ELISA) in a setting of concomitant transmission of chikungunya, dengue and Zika viruses. Int J Infect Dis 91:38\u201343","journal-title":"Int J Infect Dis"},{"issue":"1","key":"1820_CR62","doi-asserted-by":"crossref","first-page":"e3445","DOI":"10.1371\/journal.pntd.0003445","volume":"9","author":"Y-W Kam","year":"2015","unstructured":"Kam Y-W et al (2015) Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients. PLoS Negl Trop Dis 9(1):e3445\u2013e3445","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"1820_CR63","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1590\/S0037-86822007000200016","volume":"40","author":"LT Figueiredo","year":"2007","unstructured":"Figueiredo LT (2007) Emergent arboviruses in Brazil. Rev Soc Bras Med Trop 40(2):224\u2013229","journal-title":"Rev Soc Bras Med Trop"},{"key":"1820_CR64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4939-3618-2_6","volume":"1426","author":"P Gaibani","year":"2016","unstructured":"Gaibani P, Landini MP, Sambri V (2016) Diagnostic methods for CHIKV based on serological tools. Methods Mol Biol 1426:63\u201373","journal-title":"Methods Mol Biol"},{"issue":"suppl 5","key":"1820_CR65","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/infdis\/jiw245","volume":"214","author":"TM Sharp","year":"2016","unstructured":"Sharp TM et al (2016) Surveillance for chikungunya and dengue during the first year of chikungunya virus circulation in puerto rico. J Infect Dis 214(suppl 5):S475\u2013S481","journal-title":"J Infect Dis"},{"issue":"1","key":"1820_CR66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s40475-015-0036-0","volume":"2","author":"F Gobbi","year":"2015","unstructured":"Gobbi F et al (2015) Emergence and surveillance of chikungunya. Curr Trop Med Rep 2(1):4\u201312","journal-title":"Curr Trop Med Rep"},{"issue":"7","key":"1820_CR67","doi-asserted-by":"crossref","first-page":"e2331","DOI":"10.1371\/journal.pntd.0002331","volume":"7","author":"MR Capeding","year":"2013","unstructured":"Capeding MR et al (2013) Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children. PLoS Negl Trop Dis 7(7):e2331","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"1820_CR68","doi-asserted-by":"crossref","first-page":"e130696","DOI":"10.3201\/eid2008.130696","volume":"20","author":"A Roth","year":"2014","unstructured":"Roth A et al (2014) Preparedness for threat of chikungunya in the pacific. Emerg Infect Dis 20(8):e130696","journal-title":"Emerg Infect Dis"},{"key":"1820_CR69","unstructured":"PPHSN. Pacific Public Health Surveillance Network 2016 [cited 2020 3. October 2020]; Available from: https:\/\/www.pphsn.net\/index.htm."},{"issue":"29","key":"1820_CR70","doi-asserted-by":"crossref","first-page":"1800033","DOI":"10.2807\/1560-7917.ES.2018.23.29.1800033","volume":"23","author":"A Heitmann","year":"2018","unstructured":"Heitmann A et al (2018) Experimental risk assessment for chikungunya virus transmission based on vector competence, distribution and temperature suitability in Europe, 2018. Eurosurveillance 23(29):1800033","journal-title":"Eurosurveillance"},{"key":"1820_CR71","volume-title":"Cluster of autochtonous chikungunya cases in France\u201423 August 2017","author":"ECDC","year":"2017","unstructured":"ECDC (2017) Cluster of autochtonous chikungunya cases in France\u201423 August 2017. ECDC-European Centre for Disease Prevention and Control, Stockholm"},{"issue":"2","key":"1820_CR72","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11262-020-01737-5","volume":"56","author":"JJ Bugert","year":"2020","unstructured":"Bugert JJ et al (2020) Antivirals in medical biodefense. Virus Genes 56(2):150\u2013167","journal-title":"Virus Genes"},{"issue":"10","key":"1820_CR73","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/1087057113505906","volume":"18","author":"AC Patel","year":"2013","unstructured":"Patel AC (2013) Clinical relevance of target identity and biology: implications for drug discovery and development. J Biomol Screen 18(10):1164\u20131185","journal-title":"J Biomol Screen"},{"issue":"Suppl 2","key":"1820_CR74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1464-410X.2001.00112.x","volume":"88","author":"T Takenaka","year":"2001","unstructured":"Takenaka T (2001) Classical vs reverse pharmacology in drug discovery. BJU Int 88(Suppl 2):7\u201310","journal-title":"BJU Int"},{"issue":"4","key":"1820_CR75","first-page":"559","volume":"11","author":"U Rester","year":"2008","unstructured":"Rester U (2008) From virtuality to reality\u2014virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr Opin Drug Discov Devel 11(4):559\u2013568","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"12","key":"1820_CR76","doi-asserted-by":"crossref","first-page":"e28923","DOI":"10.1371\/journal.pone.0028923","volume":"6","author":"L Pohjala","year":"2011","unstructured":"Pohjala L et al (2011) Inhibitors of alphavirus entry and replication identified with a stable chikungunya replicon cell line and virus-based assays. PLoS ONE 6(12):e28923","journal-title":"PLoS ONE"},{"issue":"9","key":"1820_CR77","doi-asserted-by":"crossref","first-page":"e2423","DOI":"10.1371\/journal.pntd.0002423","volume":"7","author":"S Selvarajah","year":"2013","unstructured":"Selvarajah S et al (2013) A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis 7(9):e2423","journal-title":"PLoS Negl Trop Dis"},{"key":"1820_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.001","volume":"113","author":"C Weber","year":"2015","unstructured":"Weber C et al (2015) The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antiviral Res 113:1\u20133","journal-title":"Antiviral Res"},{"issue":"2","key":"1820_CR79","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/1087057112460091","volume":"18","author":"M Lucas-Hourani","year":"2013","unstructured":"Lucas-Hourani M et al (2013) A phenotypic assay to identify chikungunya virus inhibitors targeting the nonstructural protein nsP2. J Biomol Screen 18(2):172\u2013179","journal-title":"J Biomol Screen"},{"issue":"3","key":"1820_CR80","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0264-410X(86)90003-4","volume":"4","author":"NH Levitt","year":"1986","unstructured":"Levitt NH et al (1986) Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4(3):157\u2013162","journal-title":"Vaccine"},{"issue":"6","key":"1820_CR81","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","volume":"62","author":"R Edelman","year":"2000","unstructured":"Edelman R et al (2000) Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 62(6):681\u2013685","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"1820_CR82","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1128\/JVI.06449-11","volume":"86","author":"R Gorchakov","year":"2012","unstructured":"Gorchakov R et al (2012) Attenuation of chikungunya virus vaccine strain 181\/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J Virol 86(11):6084\u20136096","journal-title":"J Virol"},{"issue":"1","key":"1820_CR83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2010.10.009","volume":"89","author":"M Khan","year":"2011","unstructured":"Khan M et al (2011) Cellular IMPDH enzyme activity is a potential target for the inhibition of chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res 89(1):1\u20138","journal-title":"Antiviral Res"},{"key":"1820_CR84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.antiviral.2013.12.010","volume":"103","author":"AP Rathore","year":"2014","unstructured":"Rathore AP et al (2014) Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. Antiviral Res 103:7\u201316","journal-title":"Antiviral Res"},{"issue":"2","key":"1820_CR85","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2003.09.005","volume":"61","author":"S Briolant","year":"2004","unstructured":"Briolant S et al (2004) In vitro inhibition of chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 61(2):111\u2013117","journal-title":"Antiviral Res"},{"issue":"10","key":"1820_CR86","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","volume":"69","author":"L Delang","year":"2014","unstructured":"Delang L et al (2014) Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69(10):2770\u20132784","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1820_CR87","doi-asserted-by":"crossref","first-page":"e2471","DOI":"10.1371\/journal.pntd.0002471","volume":"7","author":"DJ Cruz","year":"2013","unstructured":"Cruz DJ et al (2013) Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library. PLoS Negl Trop Dis 7(10):e2471","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"1820_CR88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.01.002","volume":"98","author":"M Bassetto","year":"2013","unstructured":"Bassetto M et al (2013) Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus. Antiviral Res 98(1):12\u201318","journal-title":"Antiviral Res"},{"issue":"3","key":"1820_CR89","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.3390\/molecules19033617","volume":"19","author":"M Bourjot","year":"2014","unstructured":"Bourjot M et al (2014) Trigocherrierin A, a potent inhibitor of chikungunya virus replication. Molecules 19(3):3617\u20133627","journal-title":"Molecules"},{"key":"1820_CR90","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejmech.2014.10.042","volume":"89","author":"SS Jadav","year":"2015","unstructured":"Jadav SS et al (2015) Thiazolidone derivatives as inhibitors of chikungunya virus. Eur J Med Chem 89:172\u2013178","journal-title":"Eur J Med Chem"},{"issue":"12","key":"1820_CR91","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1172\/JCI63120","volume":"122","author":"TS Teng","year":"2012","unstructured":"Teng TS et al (2012) Viperin restricts chikungunya virus replication and pathology. J Clin Invest 122(12):4447\u20134460","journal-title":"J Clin Invest"},{"key":"1820_CR92","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2016.12.020","volume":"139","author":"R Abdelnabi","year":"2017","unstructured":"Abdelnabi R et al (2017) Protein kinases C as potential host targets for the inhibition of chikungunya virus replication. Antiviral Res 139:79\u201387","journal-title":"Antiviral Res"},{"key":"1820_CR93","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s13071-015-1104-y","volume":"8","author":"S Marlina","year":"2015","unstructured":"Marlina S et al (2015) Development of a Real-Time Cell Analysing (RTCA) method as a fast and accurate screen for the selection of chikungunya virus replication inhibitors. Parasit Vectors 8:579","journal-title":"Parasit Vectors"},{"issue":"4","key":"1820_CR94","doi-asserted-by":"crossref","first-page":"e1003312","DOI":"10.1371\/journal.ppat.1003312","volume":"9","author":"P Pal","year":"2013","unstructured":"Pal P et al (2013) Development of a highly protective combination monoclonal antibody therapy against chikungunya virus. PLoS Pathog 9(4):e1003312","journal-title":"PLoS Pathog"},{"issue":"9","key":"1820_CR95","doi-asserted-by":"crossref","first-page":"e2405","DOI":"10.1371\/journal.pntd.0002405","volume":"7","author":"D Parashar","year":"2013","unstructured":"Parashar D et al (2013) Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Negl Trop Dis 7(9):e2405","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"1820_CR96","doi-asserted-by":"crossref","first-page":"e0005637","DOI":"10.1371\/journal.pntd.0005637","volume":"11","author":"R Broeckel","year":"2017","unstructured":"Broeckel R et al (2017) Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. PLoS Negl Trop Dis 11(6):e0005637","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"1820_CR97","doi-asserted-by":"crossref","first-page":"e0007563","DOI":"10.1371\/journal.pntd.0007563","volume":"13","author":"LR Feldstein","year":"2019","unstructured":"Feldstein LR et al (2019) Estimating the cost of illness and burden of disease associated with the 2014\u20132015 chikungunya outbreak in the U.S. Virgin Islands. PLoS Negl Trop Dis 13(7):e0007563","journal-title":"PLoS Negl Trop Dis"},{"key":"1820_CR98","unstructured":"CDC. Chikungunya Virus. 2020 19. Sept. 2019 [cited 2020]; Available from: https:\/\/www.cdc.gov\/chikungunya\/geo\/index.html"},{"issue":"4","key":"1820_CR99","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejim.2012.01.009","volume":"23","author":"EJ Kucharz","year":"2012","unstructured":"Kucharz EJ, Cebula-Byrska I (2012) Chikungunya fever. Eur J Intern Med 23(4):325\u2013329","journal-title":"Eur J Intern Med"},{"issue":"4","key":"1820_CR100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar S et al (2018) Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med 379(4):327\u2013340","journal-title":"N Engl J Med"},{"issue":"1","key":"1820_CR101","doi-asserted-by":"crossref","first-page":"e0007831","DOI":"10.1371\/journal.pntd.0007831","volume":"14","author":"AL Wilson","year":"2020","unstructured":"Wilson AL et al (2020) The importance of vector control for the control and elimination of vector-borne diseases. PLoS Negl Trop Dis 14(1):e0007831\u2013e0007831","journal-title":"PLoS Negl Trop Dis"},{"issue":"suppl_2","key":"1820_CR102","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/infdis\/jiw575","volume":"215","author":"SA Ritchie","year":"2017","unstructured":"Ritchie SA, Johnson BJ (2017) Advances in vector control science: rear-and-release strategies show promise \u2026 but don\u2019t forget the basics. J Infect Dis 215(suppl_2):S103\u2013S108","journal-title":"J Infect Dis"},{"issue":"3","key":"1820_CR103","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/vbz.2009.0014","volume":"10","author":"L Alphey","year":"2010","unstructured":"Alphey L et al (2010) Sterile-insect methods for control of mosquito-borne diseases: an analysis. Vector Borne Zoonotic Dis 10(3):295\u2013311","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"286","key":"1820_CR104","first-page":"20192709","volume":"2019","author":"N Wedell","year":"1917","unstructured":"Wedell N, Price TAR, Lindholm AK (1917) Gene drive: progress and prospects. Proc Biol Sci 2019(286):20192709\u201320192709","journal-title":"Proc Biol Sci"},{"issue":"4","key":"1820_CR105","doi-asserted-by":"crossref","first-page":"e0004677","DOI":"10.1371\/journal.pntd.0004677","volume":"10","author":"MT Aliota","year":"2016","unstructured":"Aliota MT et al (2016) The wMel strain of Wolbachia reduces transmission of chikungunya virus in Aedesaegypti. PLoS Negl Trop Dis 10(4):e0004677","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"1820_CR106","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrmicro1969","volume":"6","author":"JH Werren","year":"2008","unstructured":"Werren JH, Baldo L, Clark ME (2008) Wolbachia: master manipulators of invertebrate biology. Nat Rev Microbiol 6(10):741\u2013751","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"1820_CR107","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.3390\/v7112903","volume":"7","author":"KN Johnson","year":"2015","unstructured":"Johnson KN (2015) The impact of Wolbachia on virus infection in mosquitoes. Viruses 7(11):5705\u20135717","journal-title":"Viruses"},{"key":"1820_CR108","doi-asserted-by":"crossref","first-page":"28792","DOI":"10.1038\/srep28792","volume":"6","author":"MT Aliota","year":"2016","unstructured":"Aliota MT et al (2016) The wMel strain of Wolbachia reduces transmission of zika virus by Aedes aegypti. Sci Rep 6:28792","journal-title":"Sci Rep"},{"issue":"7361","key":"1820_CR109","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nature10356","volume":"476","author":"AA Hoffmann","year":"2011","unstructured":"Hoffmann AA et al (2011) Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 476(7361):454\u2013457","journal-title":"Nature"},{"issue":"11","key":"1820_CR110","doi-asserted-by":"crossref","first-page":"e1892","DOI":"10.1371\/journal.pntd.0001892","volume":"6","author":"AF van den Hurk","year":"2012","unstructured":"van den Hurk AF et al (2012) Impact of Wolbachia on infection with chikungunya and yellow fever viruses in the mosquito vector Aedesaegypti. PLoS Negl Trop Dis 6(11):e1892","journal-title":"PLoS Negl Trop Dis"},{"key":"1820_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-02492-1","author":"E Callaway","year":"2020","unstructured":"Callaway E (2020) The mosquito strategy that could eliminate dengue. Nature. https:\/\/doi.org\/10.1038\/d41586-020-02492-1","journal-title":"Nature"},{"key":"1820_CR112","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.12688\/gatesopenres.13061.2","volume":"3","author":"P Ryan","year":"2020","unstructured":"Ryan P et al (2020) Establishment of wMel Wolbachia in Aedes aegypti mosquitoes and reduction of local dengue transmission in Cairns and surrounding locations in northern Queensland, Australia [version 2; peer review: 2 approved]. Gates Open Res 3:1547","journal-title":"Gates Open Res"},{"issue":"1","key":"1820_CR113","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s13063-020-04367-2","volume":"21","author":"KL Anders","year":"2020","unstructured":"Anders KL et al (2020) Update to the AWED (Applying Wolbachia to Eliminate Dengue) trial study protocol: a cluster randomised controlled trial in Yogyakarta, Indonesia. Trials 21(1):429","journal-title":"Trials"},{"issue":"7639","key":"1820_CR114","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/542015a","volume":"542","author":"E Callaway","year":"2017","unstructured":"Callaway E (2017) Gene drives thwarted by emergence of resistant organisms. Nature 542(7639):15","journal-title":"Nature"},{"key":"1820_CR115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1743-422X-11-183","volume":"11","author":"N Nitatpattana","year":"2014","unstructured":"Nitatpattana N et al (2014) Long-term persistence of chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand. Virol J 11:183","journal-title":"Virol J"},{"issue":"1","key":"1820_CR116","doi-asserted-by":"crossref","first-page":"e0006919","DOI":"10.1371\/journal.pntd.0006919","volume":"13","author":"G Rezza","year":"2019","unstructured":"Rezza G, Weaver SC (2019) Chikungunya as a paradigm for emerging viral diseases: evaluating disease impact and hurdles to vaccine development. PLOS Negl Trop Dis 13(1):e0006919","journal-title":"PLOS Negl Trop Dis"},{"issue":"10","key":"1820_CR117","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2019.1574149","volume":"15","author":"A Reyes-Sandoval","year":"2019","unstructured":"Reyes-Sandoval A (2019) 51 years in of chikungunya clinical vaccine development: a historical perspective. Hum Vaccin Immunother 15(10):2351\u20132358","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1820_CR118","doi-asserted-by":"crossref","first-page":"e83527","DOI":"10.1172\/jci.insight.83527","volume":"2","author":"P Roques","year":"2017","unstructured":"Roques P et al (2017) Attenuated and vectored vaccines protect nonhuman primates against chikungunya virus. JCI Insight 2(6):e83527","journal-title":"JCI Insight"},{"key":"1820_CR119","volume-title":"Valneva initiates phase 3 clinical study for its chikungunya vaccine candidate VLA1553","author":"Valneva","year":"2020","unstructured":"Valneva (2020) Valneva initiates phase 3 clinical study for its chikungunya vaccine candidate VLA1553. Valneva SE, Saint-Herblain"},{"issue":"5","key":"1820_CR120","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1128\/JVI.03453-13","volume":"88","author":"D Hallengard","year":"2014","unstructured":"Hallengard D et al (2014) Novel attenuated chikungunya vaccine candidates elicit protective immunity in C57BL\/6 mice. J Virol 88(5):2858\u20132866","journal-title":"J Virol"},{"key":"1820_CR121","volume-title":"CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI","author":"International Vaccine Institute, I.","year":"2020","unstructured":"International Vaccine Institute, I. (2020) CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI. CEPI, the Coalition for Epidemic Preparedness Innovations, Oslo, Seoul, Telangana"},{"key":"1820_CR122","volume-title":"Phase-I open label, dose-escalation clinical trial to evaluate the safety, tolerability and immunogenicity of chikungunya vaccine in healthy adults of 18 to 50 years age","author":"Clinical Trials Registry\u2014India, C.","year":"2017","unstructured":"Clinical Trials Registry\u2014India, C. (2017) Phase-I open label, dose-escalation clinical trial to evaluate the safety, tolerability and immunogenicity of chikungunya vaccine in healthy adults of 18 to 50 years age. Clinical Trials Registry\u2014India, CTRI, Hyderabad"},{"issue":"9959","key":"1820_CR123","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","volume":"384","author":"LJ Chang","year":"2014","unstructured":"Chang LJ et al (2014) Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 384(9959):2046\u20132052","journal-title":"Lancet"},{"issue":"10","key":"1820_CR124","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/infdis\/jiw431","volume":"214","author":"L Goo","year":"2016","unstructured":"Goo L et al (2016) A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all chikungunya virus genotypes. J Infect Dis 214(10):1487\u20131491","journal-title":"J Infect Dis"},{"issue":"7","key":"1820_CR125","doi-asserted-by":"crossref","first-page":"e1002142","DOI":"10.1371\/journal.ppat.1002142","volume":"7","author":"K Plante","year":"2011","unstructured":"Plante K et al (2011) Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 7(7):e1002142","journal-title":"PLoS Pathog"},{"issue":"12","key":"1820_CR126","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/infdis\/jiu014","volume":"209","author":"CJ Roy","year":"2014","unstructured":"Roy CJ et al (2014) Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis 209(12):1891\u20131899","journal-title":"J Infect Dis"},{"issue":"36","key":"1820_CR127","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","volume":"31","author":"S Brandler","year":"2013","unstructured":"Brandler S et al (2013) A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31(36):3718\u20133725","journal-title":"Vaccine"},{"issue":"5","key":"1820_CR128","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","volume":"15","author":"K Ramsauer","year":"2015","unstructured":"Ramsauer K et al (2015) Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15(5):519\u2013527","journal-title":"Lancet Infect Dis"},{"issue":"10165","key":"1820_CR129","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","volume":"392","author":"EC Reisinger","year":"2019","unstructured":"Reisinger EC et al (2019) Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet 392(10165):2718\u20132727","journal-title":"Lancet"},{"key":"1820_CR130","unstructured":"Medicine, N.N.L.o. ClinicalTrials.gov. [cited 2020 05.05.2020]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03590392"},{"key":"1820_CR131","unstructured":"Moderna. Infectious Diseases. 2019 [cited 2020 January 15]; Available from: https:\/\/www.modernatx.com\/pipeline\/therapeutic-areas\/infectious-diseases"},{"key":"1820_CR132","unstructured":"Liu, A. Moderna initiates Chikungunya vaccine human test, replaces backup Zika candidate. 2017 [cited 2019 September 19]; Available from: https:\/\/www.fiercepharma.com\/vaccines\/moderna-initiates-chikungunya-vaccine-human-test-replaces-backup-zika-candidate"},{"key":"1820_CR133","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw6647","author":"N Kose","year":"2019","unstructured":"Kose N et al (2019) A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aaw6647","journal-title":"Sci Immunol"},{"key":"1820_CR134","volume-title":"Moderna announces positive phase 1 results for the first systemic messenger RNA therapeutic encoding a secreted protein (mRNA-1944)","author":"Moderna","year":"2019","unstructured":"Moderna (2019) Moderna announces positive phase 1 results for the first systemic messenger RNA therapeutic encoding a secreted protein (mRNA-1944). Business wire, Cambridge"},{"issue":"9","key":"1820_CR135","doi-asserted-by":"crossref","first-page":"e0004007","DOI":"10.1371\/journal.pntd.0004007","volume":"9","author":"KS Plante","year":"2015","unstructured":"Plante KS et al (2015) Extended preclinical safety, efficacy and stability testing of a live-attenuated chikungunya vaccine candidate. PLoS Negl Trop Dis 9(9):e0004007","journal-title":"PLoS Negl Trop Dis"},{"key":"1820_CR136","volume-title":"Valneva reports excellent final phase 1 results for its chikungunya vaccine candidate, confirms plans","author":"Valneva Press Release","year":"2019","unstructured":"Valneva Press Release (2019) Valneva reports excellent final phase 1 results for its chikungunya vaccine candidate, confirms plans. Valneva, Saint-Herblain"},{"issue":"3","key":"1820_CR137","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","volume":"16","author":"W Akahata","year":"2010","unstructured":"Akahata W et al (2010) A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med 16(3):334\u2013338","journal-title":"Nat Med"},{"issue":"5","key":"1820_CR138","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/infdis\/jiz202","volume":"220","author":"SL Rossi","year":"2019","unstructured":"Rossi SL et al (2019) Immunogenicity and efficacy of a measles virus-vectored chikungunya vaccine in nonhuman primates. J Infect Dis 220(5):735\u2013742","journal-title":"J Infect Dis"},{"issue":"4","key":"1820_CR139","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/600381","volume":"200","author":"T Couderc","year":"2009","unstructured":"Couderc T et al (2009) Prophylaxis and therapy for chikungunya virus infection. J Infect Dis 200(4):516\u2013523","journal-title":"J Infect Dis"},{"issue":"5","key":"1820_CR140","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cell.2015.10.050","volume":"163","author":"JM Fox","year":"2015","unstructured":"Fox JM et al (2015) Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 163(5):1095\u20131107","journal-title":"Cell"},{"issue":"1","key":"1820_CR141","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chom.2015.06.009","volume":"18","author":"SA Smith","year":"2015","unstructured":"Smith SA et al (2015) Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus. Cell Host Microbe 18(1):86\u201395","journal-title":"Cell Host Microbe"},{"issue":"5","key":"1820_CR142","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.cell.2015.11.006","volume":"163","author":"M Kielian","year":"2015","unstructured":"Kielian M, Saphire EO (2015) Potent antibody protection against an emerging alphavirus threat. Cell 163(5):1053\u20131054","journal-title":"Cell"},{"key":"1820_CR143","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.virol.2015.03.025","volume":"479\u2013480","author":"RJ Kuhn","year":"2015","unstructured":"Kuhn RJ et al (2015) Shake, rattle, and roll: impact of the dynamics of flavivirus particles on their interactions with the host. Virology 479\u2013480:508\u2013517","journal-title":"Virology"},{"issue":"suppl 5","key":"1820_CR144","doi-asserted-by":"crossref","first-page":"S506","DOI":"10.1093\/infdis\/jiw324","volume":"214","author":"AM Clayton","year":"2016","unstructured":"Clayton AM (2016) Monoclonal antibodies as prophylactic and therapeutic agents against chikungunya virus. J Infect Dis 214(suppl 5):S506-s509","journal-title":"J Infect Dis"},{"key":"1820_CR145","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fimmu.2020.00592","volume":"11","author":"S Schrauf","year":"2020","unstructured":"Schrauf S et al (2020) Current efforts in the development of vaccines for the prevention of zika and chikungunya virus infections. Front Immunol 11:592","journal-title":"Front Immunol"},{"key":"1820_CR146","volume-title":"United States Code","author":"FDA, F.a.D.A.","year":"2018","unstructured":"FDA, F.a.D.A. (2018) United States Code, 2018 Edition, Title 42\u2014The public health and welfare. United States Code. U.S. Government Publishing Office, Washington DC"},{"key":"1820_CR147","volume-title":"Code of Federal Regulations (CFR)","author":"FDA, F.a.D.A.","year":"2020","unstructured":"FDA, F.a.D.A. (2020) CFR\u2014Title 21\u2014Food and Drugs, Section \u00a7 314.126\u2014adequate and well-controlled studies. In: U.S.D.o.H.a.H.S. (HHS) (ed) Code of Federal Regulations (CFR). Food and Drug Administration (FDA), Washington DC"},{"issue":"37","key":"1820_CR148","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1016\/j.vaccine.2017.07.065","volume":"35","author":"S Yang","year":"2017","unstructured":"Yang S et al (2017) Regulatory considerations in development of vaccines to prevent disease caused by chikungunya virus. Vaccine 35(37):4851\u20134858","journal-title":"Vaccine"},{"key":"1820_CR149","volume-title":"WHO consultation on Chikungunya vaccine evaluation, in R&D blueprint","author":"WHO","year":"2018","unstructured":"WHO (2018) WHO consultation on Chikungunya vaccine evaluation, in R&D blueprint. World Health Organisation (WHO), Geneva"},{"key":"1820_CR150","doi-asserted-by":"publisher","DOI":"10.1007\/82_2019_175","author":"VR DeFilippis","year":"2019","unstructured":"DeFilippis VR (2019) Chikungunya virus vaccines: platforms, progress, and challenges. Curr Top Microbiol Immunol. https:\/\/doi.org\/10.1007\/82_2019_175","journal-title":"Curr Top Microbiol Immunol"},{"key":"1820_CR151","volume-title":"Vaccines and Related Biological Products Advisory Committee November 8, 2019","author":"VRBPAC, V.R.B.P.A.C","year":"2018","unstructured":"VRBPAC, V.R.B.P.A.C (2018) Vaccines and Related Biological Products Advisory Committee November 8, 2019. FDA US Food & Drug Administration, Silver Spring"},{"key":"1820_CR152","volume-title":"Code of Federal Regulations (CFR)","author":"FDA, F.a.D.A.","year":"2020","unstructured":"FDA, F.a.D.A. (2020) CFR\u2014Title 21\u2014Food and Drugs, Section \u00a7 312.300 General. In: U.S.D.o.H.a.H.S. (HHS) (ed) Code of Federal Regulations (CFR). Food and Drug Administration (FDA), Washington DC"},{"key":"1820_CR153","volume-title":"Code of Federal Regulations (CFR)","author":"FDA, F.a.D.A.","year":"2020","unstructured":"FDA, F.a.D.A. (2020) CFR\u2014Title 21\u2014Food and Drugs, Section \u00a7 601.41 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. In: U.S.D.o.H.a.H.S. (HHS) (ed) Code of Federal Regulations (CFR). Food and Drug Administration (FDA), Washington DC"},{"key":"1820_CR154","volume-title":"Code of Federal Regulations (CFR)","author":"FDA, F.a.D.A.","year":"2020","unstructured":"FDA, F.a.D.A. (2020) CFR - Title 21 - Food and Drugs, Section \u00a7 601.91 Approval based on evidence of effectiveness from studies in animals. In: U.S.D.o.H.a.H.S. (HHS) (ed) Code of Federal Regulations (CFR). Food and Drug Administration (FDA), Washington DC"}],"container-title":["Virus Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-020-01820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11262-020-01820-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-020-01820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:40:24Z","timestamp":1744152024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11262-020-01820-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":154,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1820"],"URL":"https:\/\/doi.org\/10.1007\/s11262-020-01820-x","relation":{},"ISSN":["0920-8569","1572-994X"],"issn-type":[{"value":"0920-8569","type":"print"},{"value":"1572-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}